en
svPress releases
Press release 2024-09-19
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Regulatory press release 2024-08-07
Interim Report Second Quarter 2024
Regulatory press release 2024-07-26
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
Regulatory press release 2024-07-09
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
Regulatory press release 2024-05-31
New number of shares and votes in Xspray Pharma after TO6
-
Latest report
Interim Report Q2 2024 -
Subscribe
Get our latest press releases and reports
